Alcohol intake increases the risk of HCC in hepatitis C virus-related cirrhosis: a prospective study.

[en] Background & Aims:Whether alcohol intake increases the risk of complications in patients with HCV-related cirrhosis remains unclear. The aim of this study was to determine the impact of alcohol intake and viral eradication on the risk of hepatocellular carcinoma (HCC), decompensation of cirrhosis and death. Methods: Data on alcohol intake and viral eradication were prospectively collected in 192 patients with compensated HCVrelated cirrhosis. Results: 74 patients consumed alcohol (median alcohol intake: 15 g/day); 68 reached viral eradication. During a median followup of 58 months, 33 patients developed HCC, 53 experienced at least one decompensation event, and 39 died. The 5-year cumulative incidence rate of HCC was 10.6% (95% CI: 4.6–16.6) in abstainers vs. 23.8% (95% CI: 13.5–34.1) in consumers (p = 0.087), and 2.0% (95% CI: 0–5.8) vs. 21.7% (95% CI: 14.2–29.2) in patients with and without viral eradication (p = 0.002), respectively. The lowest risk of HCC was observed for patients without alcohol intake and with viral eradication (0%) followed by patients with alcohol intake and viral eradication (6.2% [95% CI: 0–18.4]), patients without alcohol intake and no viral eradication (15.9% [95% CI: 7.1– 24.7]), and patients with alcohol intake and no viral eradication (29.2% [95% CI: 16.5–41.9]) (p = 0.009). In multivariate analysis, lack of viral eradication and alcohol consumption were associated with the risk of HCC (hazard ratio for alcohol consumption: 3.43, 95% CI: 1.49–7.92, p = 0.004). Alcohol intake did not influence the risk of decompensation or death. Conclusions: Light-to-moderate alcohol intake increases the risk of HCC in patients with HCV-related cirrhosis. Patient care should include measures to ensure abstinence. Lay summary:Whether alcohol intake increases the risk of complications in patients with HCV-related cirrhosis remains unclear. In this prospective study, light-to-moderate alcohol intake was associated with the risk of hepatocellular carcinoma in multivariate analysis. No patients who did not use alcohol and who reached viral eradication developed hepatocellular carcinoma during follow-up. The risk of hepatocellular carcinoma increased with alcohol intake or in patients without viral eradication and was highest when alcohol intake was present in the absence of viral eradication. Patients with HCV-related cirrhosis should be strongly advised against any alcohol intake. Patient care should include measures to ensure abstinence.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Vandenbulcke, H

Moreno, C

Colle, I

Knebel, JF

Francque, S

Sersté, T

George, C

de Galocsy, C

Laleman, W

DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive

More authors (11 more)

Language :

English

Title :

Alcohol intake increases the risk of HCC in hepatitis C virus-related cirrhosis: a prospective study.

Publication date :

2016

Journal title :

Journal of Hepatology

ISSN :

0168-8278

eISSN :

1600-0641

Publisher :

Elsevier, Oxford, United Kingdom

Volume :

Pages :

543-551

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 October 2016

Statistics

Number of views

232 (9 by ULiège)

Number of downloads

442 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

[1] EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
[2] Deltenre, P., Studies on the epidemiology of hepatitis B and C virus infections are still needed. J Hepatol 62 (2015), 1225–1227.
[3] Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A.M., Rosmorduc, O., Poupon, R.E., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998), 1435–1440.
[4] Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43 (2006), 1303–1310.
[5] Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997), 825–832.
[6] Bedogni, G., Miglioli, L., Masutti, F., Ferri, S., Castiglione, A., Lenzi, M., et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 103 (2008), 2248–2253.
[7] Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Muhlberger, N., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 143, 2012, e14.
[8] Deuffic-Burban, S., Deltenre, P., Louvet, A., Canva, V., Dharancy, S., Hollebecque, A., et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 49 (2008), 175–183.
[9] Thomas, D.L., Astemborski, J., Rai, R.M., Anania, F.A., Schaeffer, M., Galai, N., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (2000), 450–456.
[10] Harris, H.E., Ramsay, M.E., Andrews, N., Eldridge, K.P., Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 324 (2002), 450–453.
[11] Tagger, A., Donato, F., Ribero, M.L., Chiesa, R., Portera, G., Gelatti, U., et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81 (1999), 695–699.
[12] Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997), 875–881.
[13] Sobesky, R., Mathurin, P., Charlotte, F., Moussalli, J., Olivi, M., Vidaud, M., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 116 (1999), 378–386.
[14] Amin, J., Law, M.G., Bartlett, M., Kaldor, J.M., Dore, G.J., Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 (2006), 938–945.
[15] Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521 521, e1–e6.
[16] Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.P., Giuily, N., Castelnau, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52 (2010), 652–657.
[17] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2013), 2584–2593.
[18] Veldt, B.J., Heathcote, E.J., Wedemeyer, H., Reichen, J., Hofmann, W.P., Zeuzem, S., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007), 677–684.
[19] Bruno, S., Crosignani, A., Facciotto, C., Rossi, S., Roffi, L., Redaelli, A., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
[20] Iacobellis, A., Siciliano, M., Perri, F., Annicchiarico, B.E., Leandro, G., Caruso, N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46 (2007), 206–212.
[21] Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005), 105–114.
[22] Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999), 174–181.
[23] Innes, H.A., Hutchinson, S.J., Allen, S., Bhattacharyya, D., Bramley, P., Delahooke, T.E., et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 54 (2011), 1547–1558.
[24] Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20 (1994), 15–20.
[25] Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
[26] Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005), 48–54.
[27] European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53 (2010), 397–417.
[28] Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 62 (2015), 292–302.
[29] Gray, R.J., A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
[30] Campbell, J.V., Hagan, H., Latka, M.H., Garfein, R.S., Golub, E.T., Coady, M.H., et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 81 (2006), 259–265.
[31] White, I.R., Altmann, D.R., Nanchahal, K., Alcohol consumption and mortality: modeling risks for men and women at different ages. BMJ, 325, 2002, 191.
[32] Trinchet, J.C., Bourcier, V., Chaffaut, C., Ait Ahmed, M., Allam, S., Marcellin, P., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
[33] Morgan, T.R., Mandayam, S., Jamal, M.M., Alcohol and hepatocellular carcinoma. Gastroenterology 127 (2004), S87–S96.
[34] Rigamonti, C., Mottaran, E., Reale, E., Rolla, R., Cipriani, V., Capelli, F., et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 38 (2003), 42–49.
[35] McKillop, I.H., Schrum, L.W., Role of alcohol in liver carcinogenesis. Semin Liver Dis 29 (2009), 222–232.
[36] Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998), 1687–1695.
[37] Backus, L.I., Boothroyd, D.B., Phillips, B.R., Belperio, P., Halloran, J., Mole, L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol, 9, 2011, e1.
[38] Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnu, L., Mazzella, G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
[39] Mathurin, P., Deltenre, P., Effect of binge drinking on the liver: an alarming public health issue?. Gut 58 (2009), 613–617.
[40] Degos, F., Christidis, C., Ganne-Carrie, N., Farmachidi, J.P., Degott, C., Guettier, C., et al. Hepatitis C virus-related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000), 131–136.
[41] Benvegnu, L., Gios, M., Boccato, S., Alberti, A., Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004), 744–749.